Search
News
Pre-Bell | Wall St Futures Rise; SOXL Up 8%; TSMC and ASML Up 6%; Broadcom And AMD Up 2%; Trip.Com Down 4%
01 Stock MarketAs of Jan 15, U.S. stock index futures are modestly higher, led by strength in technology and semiconductors. Dow futures rose 0.14%, S&P 500 futures gained 0.31%, and Nasdaq 100 futures advanced 0.74%. Gains in chip-related names and AI-linked themes are supporting risk appetite, whi...Tiger News
Thu, Jan 15
Bipartisan Plan Aims to Create U.S. Reserve for Critical Minerals
A bipartisan group of lawmakers will introduce new legislation Thursday to establish a $2.5 billion "Strategic Resilience Reserve" (SRR) for critical minerals, Axios has learned.Why it matters: President Trump is bringing his prospector's pick to nearly every corner of the globe — including Ukraine,...Tiger News
Thu, Jan 15
Premarket Movers | Trip.com Drops Another 5% After a 17% Decline in Prior Session; Alibaba Falls 1%; Sidus Space Rockets 10%
Trip.com dropped nearly 5% in premarket trading after a 17% decline in prior session. China's top market regulator said an investigation is underway over Trip.com Group's alleged antitrust conduct.The regulator said Trip.com, one of China's biggest online travel agencies, allegedly abused its domina...Tiger News
Thu, Jan 15
Storage Shares Shine. SanDisk up over 4% as Bernstein Raises Its PT to $580; Micron up over 3%; Western Digital, Seagate up About 2%
SanDisk up over 4% as Bernstein raised its price target on SanDisk to $580; Micron up over 3%; Western Digital, Seagate up over 2%.SanDisk Corporation shares got a Street-high price target from Bernstein, which said tight NAND supply and sharp price increases make the memory maker a top beneficiary ...Tiger News
Thu, Jan 15
Chip Stocks Rally as TSMC Q4 Profit Leaps to Record. SOXL up Nearly 6%; Applied Materials, ASML up over 5%; TSMC up 4%; Micron up over 2%
Semiconductor stocks gained in premarket trading. TSMC, the world's main producer of advanced AI chips and a major supplier to Nvidia, on Thursday posted a 35% jump in fourth-quarter profit to record levels that handily beat market forecasts.SOXL up nearly 6%; Applied Materials, ASML rose over 5%; ...Tiger News
Thu, Jan 15
24H | Semiconductor Stocks Jump After TSMC Expects 2026 Capex of $52-56 Bln
Semiconductor stocks gained in overnight trading, as TSMC said its capital expenditure would be higher over the next three years and forecasts 2026 capex of $52 billion to $56 billion.ASML rose 5%; Applied Materials and Lam Research rose 4%; Direxion Daily Semiconductors Bull 3x Shares and KLA rose ...Tiger News
Thu, Jan 15
Crypto Daily | Bitcoin Surpasses Above $96,000; Coinbase CEO Brian Armstrong Pulls Support for Crypto Market-Structure Bill
Crypto Daily is our column tracking crypto market trends, offering timely insights and valuable updates to keep you informed.Crypto NewsBitcoin (BTC) Surpasses Above $96,000 with 1.64% Increase in 24 HoursBitcoin surpassed above $96,000 and is now trading at $96,435, with 1.64% increase in 24 hours....Tiger News
Thu, Jan 15
WuXi XDC issues positive profit alert, to acquire BioDlink in bid to strengthen ADC CDMO lead
January 14, 2026 — WuXi XDC has issued a positive profit alert for fiscal 2025 and announced a cash tender offer for BioDlink, whose shares were suspended from trading at 9am on December 29 pending details of the bid.The alert underscores the ADC CRDMO leader’s strong performance: it forecasts 45% year-on-year revenue growth in 2025, alongside over 70% gross profit growth and more than 45% growth in adjusted net profit (excluding interest income and expenses). Stripping out exchange rate fluctuations, adjusted net profit growth is projected to hit 65%.A pioneer in the ADC CRDMO space, WuXi XDC has driven synergistic growth through organic expansion and strategic acquisitions amid strong business momentum. The BioDlink acquisition will boost its operational capacity in China, expand production scale, enhance support for biotech firms via value-added services, broaden its project portfolio and customer base, and reinforce its leading position in the ADC CDMO sector."Capital for time": WuXi XDC targets CDMO capacity bottlenecksThe bioconjugate drug industry has reached a commercial inflection point as clinical pipelines expand, widening the capacity gap. Public data shows 21 ADC drugs had been approved globally by end-December 2025. Emerging classes such as AOCs, RDCs and PDCs are advancing rapidly with robust late-stage pipelines, emerging as new growth drivers in biopharma.Against accelerating global bioconjugate commercialisation, insufficient capacity has become a major constraint for CDMOs. Rapid pipeline expansion and upcoming commercial demand have made "capacity delivery capability" a core competitive advantage and key metric for investors assessing CDMO growth potential.For leading CDMOs, the approach to resolving capacity bottlenecks directly shapes market influence. Building new production lines—from site selection and construction to certification—typically takes three to five years, too slow to keep pace with surging bioconjugate commercial demand. WuXi XDC’s proactive strategy of acquiring existing facilities, using efficient capital operations to capture market opportunities, stands out as optimal in the sector. The BioDlink deal aligns with this logic, enabling rapid capacity expansion via external integration and ensuring steady performance growth.Building on strengths: Tech platforms and talent drive growthWuXi XDC leads the industry with advanced conjugation and payload-linker technologies, and extensive bioconjugate drug development experience. It has rolled out innovative platforms including WuXiDARx™, dual-payload conjugation, X-LinC linker, and WuXiTecan-1/2 payload-linker technologies.To meet global customers’ diverse ordering needs and complex R&D requirements, it adopts a two-pronged "independent R&D plus external collaboration" strategy to build an integrated technology platform. This enriches technical reserves, boosts front-end R&D pipeline generation, and strengthens its R&D leadership.Talent is critical to the bioconjugate CDMO sector, but rapid industry growth has outpaced professional talent supply, a key growth constraint. WuXi XDC has long prioritised talent development; its workforce exceeded 2,600 by end-2025. The expanded professional team has formed a talent cluster, underpinning long-term growth.Riding the wave: WuXi XDC’s global capacity pushData from PharmaCube’s NextPharma shows China’s innovative drug overseas licensing transactions hit $135.655bn in 2025, including $7bn in upfront payments across 157 deals—far outstripping 2024’s $51.9bn and 94 transactions. Overseas licensing has seen explosive growth, with upfront payments and total volume at record highs. As a key bioconjugate segment, ADCs are a focus for global capital. WuXi XDC has delivered standout performance here, with steady post-listing revenue growth underscoring both the bioconjugate CDMO track’s potential and the company’s core competitiveness.Sustained business growth has made capacity expansion a key driver of high growth. By end-December 2025, WuXi XDC had worked with over 640 global customers on 252 iCMC projects. It also holds 18 PPQ projects and one commercial project, with nearly 1,000 production batches of drug substance (DS) and drug product (DP). These figures highlight strong market expansion and capacity deployment, reflecting robust demand for its services.The industry’s capacity shortage is both quantitative and structural, marked by a lack of "high-quality, integrated" capacity. Hundreds of ADCs globally are in active clinical phases, creating strong demand for commercial capacity. Meanwhile, bioconjugates’ complex production processes, high industry barriers and long supply chains have further widened the gap.Against this backdrop, WuXi XDC has established capacity in Wuxi, Jiangyin, Hefei (China) and Singapore. This global network meets global customers’ local production needs, improves operational efficiency via coordinated capacity allocation, strengthens its bioconjugate CDMO lead, and allows it to fully capture industry growth opportunities.Table: WuXi XDC’s capacity layout as of end-2025 Layout Capacity Wuxi Site XBCM1(Conjugation DS):5-500L per batch XBCM2 L1&L2(Dual-function lines for antibody and conjugation DS): 50L to 2000L per batch for monoclonal antibody intermediates orup to 2000L of DS per batch Conjugation DP Lines: XDP1:annual capacity of 3 million vials XDP2:annual capacity of 5 million vials XDP3:annual capacity of 7 million vials XDP5:annual capacity of 12 million vials, expected to GMP release in 2027 XDP6:annual capacity of 10 million vials, expected to GMP release by late 2027 / early 2028 XPLM1(Kilogram-scale payload-linker Line, business from former Changzhou site is being gradually transferred to Wuxi site) Singapore Site XBCM3(Dual-function line for antibody and conjugation DS): 50L to 2000L per batch for monoclonal antibody intermediates orup to 2000L of DS per batch, expected to GMP release in 2026 XBCM4(Conjugation DS):up to 500L per batch, expected to GMP release in 2026 XDP4(Conjugation DP):annual capacity of 8 million vials, expected to be operational in 2026 Jiangyin Site Integrated Commercial Manufacturing Site:serves as a nearby expansion for Wuxi site, including large-scale commercial small molecule production and conjugation production workshops. Hefei Site Non-GMP Manufacturing:Peptide annual capacity of ~600 batches, ~30kg GMP Manufacturing:Peptide annual capacity of ~200 batches, ~10kg Data source: Company filingsWuXi XDC to sustain capacity expansion driveLooking ahead, WuXi XDC will continue to advance overseas capacity expansion steadily and proactively, further entrenching its global leadership in the bioconjugate CDMO sector.In September 2025, the company completed a $350m refinancing, leveraging strong performance and industry reputation. Combined with a previous $200m credit facility and operational reserves, it has built a sufficient capital pool to support global capacity expansion.Backed by solid capital and mature expansion experience, WuXi XDC will pursue overseas capacity growth at an "active yet prudent" pace. It is evaluating global expansion opportunities to optimise its production network—moves that will enable local delivery, deepen penetration in the global bioconjugate CDMO sector, and reinforce its industry lead.OutlookWuXi XDC’s accelerated capacity deployment mirrors the rapid growth of ADC and other bioconjugate industries, driving the CDMO sector into a golden growth period. Frost & Sullivan data shows the global ADC drug market reached $17.2bn in 2025, with a 30.6% compound annual growth rate (CAGR) from 2023 to 2032, and is set to exceed $115.1bn by 2032. The global ADC outsourcing market is also growing strongly, projected to hit $11bn by 2030 with a 28.4% CAGR from 2022 to 2030. High growth in both sectors offers ample room for CDMO expansion.Capacity shortages are a phased challenge in the booming bioconjugate CDMO industry, unlikely to be fully resolved short-term. Over the medium to long term, however, new capacity from leading players and rising industry concentration will ease the supply-demand imbalance. WuXi XDC’s early focus on "acquisition plus expansion"—backed by accurate industry trend judgment—has secured its edge in current capacity competition and positioned it to dominate the future bioconjugate CDMO landscape, leveraging strengths in capacity scale, technical barriers and global reach.Sources1. Hong Kong Exchanges and Clearing (HKEX)2. WuXi XDC3. Frost & Sullivan4. PharmaCube5. Insight Database6. WuXi XDC presentation, 2025 Jefferies London Healthcare Conference15/01/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Thu, Jan 15
3 Singapore Dividend Stocks Yielding Over 5% That Can Beat Inflation
For investors seeking returns, stocks with high dividend yields are undoubtedly highly attractive, especially when inflation remains at a high level.If the yield exceeds 5%, investors will feel like they have won a big prize, as it can bring them immediate and tangible cash flow.The key point is tha...Tiger News
Thu, Jan 15
24H | Sidus Space Jumps over 7%; Datavault AI Rockets 10%; RF Industries Pops 19%; BRC Group Surges 36%
Sidus Space shares jumped over 7% in overnight trading after a 20% rally in prior trading session. Sidus Space, Inc. is transitioning from low-margin contract manufacturing to a high-potential space tech and defense intelligence company, catalyzed by inclusion in the $151B MDA SHIELD contract pool.D...Tiger News
Thu, Jan 15
24H | Silver stocks and ETFs Sink as Spot Silver Falls Below $90; Toyota Gains 4%
US-listed shares of Toyota gained 4% in overnight trading. Toyota Motor said on Wednesday it had agreed to raise its offer for group firm Toyota Industries to 18,800 yen ($118.11) per share as part of the plan to take the forklift maker private. The Japanese automotive giant had previously offered ...Tiger News
Thu, Jan 15
S.F. Holding and J&T in HK$8.3 Billion Cross-Share Subscription to Deepen Strategic Ties
S.F. Holding and J&T agreed to a reciprocal share subscription worth HK$8.3 billion each.The cross-holdings will give S.F. about 8.45% of J&T and J&T about 4.29% of S.F., pending satisfaction of conditions.Tiger News
Thu, Jan 15
OpenAI Signs $10 Billion Deal With Cerebras for AI Computing
OpenAI signed a multiyear deal to use hardware from Cerebras Systems Inc. for 750 megawatts’ worth of computing power, an alliance that will support the company’s rapid build-out of AI infrastructure.OpenAI will use Cerebras as a supplier of computing to get faster response times when running AI modTiger News
Thu, Jan 15
Post-Bell | Wall Street Ends Lower; Tesla Drops 2%; Nvidia Falls 1%; Intel Gains 3%; Silver ETFs and Rare Earth Stocks Jump
The U.S. major indexes closed as follows: the Dow Jones down 0.09% at $49,149.63; the S&P 500 down 0.53% at $6,926.60; and the Nasdaq Composite down 1.00% at $23,471.75.Unusual-move stocks showed sharp divergences. Notably, AGQ up 15.77% at $266.56; SLV up 7.58% at $84.56; and CRML up 32.58% at $17....Tiger News
Wed, Jan 14
Featured Tools
Top News
Qualcomm Stock Holds Rising Trendline as Amazon AI Deal Puts $182.70 Breakout in Focus
SpaceX Stock Price Forecast: As Stock Lockups Intensify, Can SPCX Peak at $225 by 2027?
Anthropic Targets $2 Trillion Valuation as 2026 US IPO Proceeds Hit Record, Yet New Stocks Lag Market
Tesla Stock Price Forecast: Morgan Stanley Sees Semi Truck Generating $17 Billion in Software Revenue, Can the Stock Continue Its Recovery?
ExxonMobil Stock Holds $163.76 as $100+ Oil and Permian Growth Put $166.65 in Focus
Market Movers
Ethereum (ETHUSD) Is down 1.22% on Sep 13: What Do On-Chain Data and Market Sentiment Show?
2 hours ago
ETHUSD
--
XRP (XRPUSD) Is down 1.08% on Sep 13: What Do On-Chain Data and Market Sentiment Show?
2 hours ago
XRPUSD
--